Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup Arbor

Chiesi Global Rare Diseases is committing up to $115 million to begin a collaboration on Arbor Biotechnologies’ in vivo gene-editing therapy for primary hyperoxaluria type 1, an inherited liver disorder. It’s the rare disease company’s first foray into genetic medicines. The post Chiesi’s Rare Disease Strategy Expands to Genetic Meds via Alliance With CRISPR Startup…

Read More

John Zutter, Lantern Care

John Zutter is the CEO of Lantern Care which is a company managing specialty care. It has evolved from a centers of excellence model, and changed its name from Employers Direct earlier this year. The trick is product expansion into the expensive stuff, especially cancer care, infusion and specialty surgery. John has thought a lot…

Read More

Aneesh Chopra talks Medicare Advantage

Aneesh Chopra (these days at Arcadia) and Matthew Holt got into a discussion of how Medicare Advantage is doing. Working with APG (America’s Physician Groups), his company Arcadia found that Medicare Advantage companies who paid capitation got better outcomes than those who were paying FFS for different patients to the SAME doctors. We got into…

Read More